Photo courtesy of Central China Agricultural University
Photo courtesy of Central China Agricultural University Recently, the research results of the collaboration between Professor Jin Honglin's group of Huazhong Agricultural University's School of Biomedicine and Health and Professor Yang Kunyu's group of Tongji Medical College of Huazhong University of Science and Technology were published in Nano Today
Nano Today Immunotherapy, especially the immune checkpoint block (ICB) targeting the programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) pathway, has changed the paradigm of cancer treatment
The study found that the ultrafiltration concentrate (RT-UF) of tumor cells after radiotherapy can effectively stimulate the activation and maturation of dendritic cells
To this end, the team independently developed a therapeutic peptide hydrogel cross-linked with PEG and melittin-peptide, which has the characteristics of slow drug release, improved cell membrane permeability, and rapid induction of tumor cell death
The data shows that the combination of UF@MRP and anti-PD -1 monoclonal antibody can cure about 43% of mice with malignant ascites, and produce a strong immune memory effect on the cured mice
The study found that the radiotherapy ultrafiltrate has a strong immunomodulatory function, which can reshape the tumor immune microenvironment; through the optimized melittin hydrogel loaded with the radiotherapy ultrafiltrate, it can exert a strong anti-tumor effect; Ascites mice are used as a model, and a concept of "indirect tumor radiotherapy" is proposed, which realizes the effective control of locally advanced and extensively metastatic tumors, and has strong clinical translational value
This research was funded by the Excellent Youth Fund Project of the National Natural Science Foundation of China
Related paper information: https://doi.
https://doi.
org/10.
1016/j.
nantod.
2021.
101323
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![3-fluorodibenzo[b,d]furan](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
![2,6-Dibromo-4,4-bis(2-ethylhexyl)-4H-silolo[3,2-b:4,5-b']dithiophene](https://file.echemi.com/fileManage/upload/canonicalSmiles/20220811/27c7aefc886740ceb896628aa7d359ad.png)
